Archive for October, 2007
Platinum Television Group to feature States? Anti-Tobacco Marketing Campaigns
Deerfield Beach, FL January 21 2004–To reduce the negative health effects of smoking, everyone knows the best thing to do is to quit. Public health authorities do not endorse either smoking fewer cigarettes or switching to lower tar and nicotine brands as a satisfactory way of reducing risk. In fact, one of the required cigarette warnings for packages and advertisements in the U.S. now is, “SURGEON GENERAL’S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.”
In spite of the continuing release of information relative to the serious potential health consequences of tobacco consumption and label warnings, one in four Americans continues to smoke. Individual states have generally done a creditable job of getting information into the hands of smokers, as evidenced by the fact that half of smoking Americans have tried to quit smoking within the last year. But they have not succeeded.
While it can be very difficult to quit smoking, there are some tips to help.
?Today?s Family,? a production of Platinum Television Group, a leading producer of educational programming for the modern market, recognizes the urgency of this subject, and will produce segments on individual states? anti-marketing efforts and provide tips and tools that smokers can employ to increase their chances of success.
The show will feature different approaches to dealing with the problems of smoking cessation, and will examine the outstanding characteristics of each. What works, and for whom, and why? Various aspects of quitting smoking will be considered for each program and will cover topics such as:
n
Specific strategies the state has employed that have been proven effective;
n
Tips to help people quit by learning new skills and behaviors;
n
Tips to keep teens and young people from smoking;
n
A report on the effectiveness of medications and how to use them properly
n
Dealing with relapses.
?Today?s Family? presents a fast-paced contemporary format showcasing issues of relevance to families, with information on new products, trends and ideas. It is aired on local networks, and produced by Platinum Television Group. Members of its Advisory Board include AARP, Alzheimer?s Association, American Academy of Pediatrics, AAHSA (American Association of Home & Services for the Aging), American Cancer Society, American Dietetic Association, Dan Marino Foundation, DARE (Drug Abuse Resistance Education), Safe Kids, School Board of Broward County, and Travel Industry Association.
Platinum Television Group ? Setting the Standard in Educational Programming
No commentsNew report provides important benchmark tool for deal-makers - Potential high returns for companies licensing in and out early-stage products YORK, UNITED KINGDOM (27 December 2003)
YORK, UNITED KINGDOM December 26 2003–Early stage partnering is still in high demand. Licensees are increasingly seeking earlier stage compounds to supplement internal R&D efforts. Licensors, in particular emerging pharmaceutical and biotech companies, have two key strategic reasons for entering into deals ? one is to provide short term financing and endorsement of their technologies, the other is to support changes in their business models as companies move from being simple suppliers of technology to fully integrated pharmaceutical companies (FIPCOs).
Within a secretive industry, it is difficult for pharmaceutical and biotech companies to obtain accurate benchmarks for deal terms. Most companies, whilst wishing to explore creative deal making options, still wish to reassure management and shareholders that the offer from the other side is competitive with industry trends. Such data has not been readily available - until the publication of ?Early Stage and Discovery Deals: Strategy, Structure and Payment Terms?, the latest report from the Bridgehead Pharmalicensing Group.
The report, by Pharmalicensing founder Steve Poile and Head of Publishing Suzanne Elvidge, is an in-depth review of licensing structures and strategies for discovery and preclinical deals, supported with case studies and deals data analysis. The publication includes press releases and the text of contracts from real early stage deals, allowing the reader to explore the actual deal terms in use in the industry today.
?Early-stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing access to promising new and emerging technologies, even though the risk of compound failure is high. Deal complexity is increasing both in terms of financial reward structures and exchange of non-monetary capabilities. We have produced a report which breaks down this complexity, providing guidelines for dealmakers in this highly competitive area?, according to author Steve Poile.
?By providing real-world data and case studies, this report will help dealmakers to benchmark future deal structures and strategies?, co-author Suzanne Elvidge added.
Brief contents
Executive summary
Why do companies partner early-stage compounds?
The evolving role of partnering in biopharmaceutical development
Early-stage deal strategies and structures
Payment strategies
How to make the right deal
Deal terms and trends - a data analysis of early-stage deals
Appendices
The report is available for ?1200/$1950/?1950 , in print or PDF format. For further details, please go to www.pharmalicensing.com/reports or call +44 1904 520464.
About Steve Poile
Steve Poile is the founder of Pharmalicensing and a director of the Bridgehead Pharmalicensing Group. Steve was Technology Licensing Manager and Competitor Intelligence Manager for Reckitt Benckiser Pharmaceutical Division, where he was responsible for sourcing and securing novel therapeutic and drug delivery technologies, as well as developing the company?s competitor intelligence capability. Previously, Steve was a research scientist at SmithKline Beecham, working in the areas of dermatology, gastroenterology and drug delivery. Steve was responsible for founding Pharmalicensing in 1998. Steve is actively involved in assisting client companies who seek business partners in the global biopharmaceutical sector, to achieve their partnering goals. He is an active member of the Licensing Executive Society, and speaks regularly on the topics of finding partners and deal terms.
About Suzanne Elvidge
Suzanne Elvidge is the Head of Publishing at the Bridgehead Pharmalicensing Group. She is the Editor of Partnering Focus, Pharmalicensing?s magazine for the partnering community, and the company?s weekly electronic newsletter, as well as writing and commissioning in-depth industry and legal reports. Suzanne has worked in medical and scientific publishing for 13 years, including six years at IMS Health on the pharmaceutical R&D newsletter R&D focus, and three years in medical education and communications with Healthworld, working on a variety of client accounts in a wide range of therapeutic areas.
About the Bridgehead Pharmalicensing Group
The Bridgehead Pharmalicensing Group, the result of a merger between Pharmalicensing Ltd and Bridgehead Technologies Ltd in May 2003, is a full service business supplying licensing, partnering and consulting services to companies worldwide, ranging from small biotechnology start-ups to leading pharmaceutical and medical companies. Pharmalicensing is the leading multi-channel business marketing tool for biopharma companies.
Ears ringing?
Brain researchers at Johns Hopkins have discovered how cells in the developing ear make their own noise, long before the ear is able to detect sound around them. The finding, reported in this weeks Nature, helps to explain how the developing auditory system generates brain activity in the absence of sound. It also may explain why people sometimes experience tinnitus and hear sounds that seem to come from nowhere……..
Original post by Health news from medicineworld.org
No commentsOpium and marijuana research go underground
The worlds leading expert on the opium poppy has joined forces with scientists working on another infamous drug-producing plant cannabis in hopes of finding new uses for the much-maligned sources of heroin and marijuana. Peter Facchini, professor of Biological Sciences and Canada Research Chair in Plant Biotechnology, has received a $650,000 NSERC Strategic Project Grant to create new varieties of opium poppy and cannabis that can be used for medicinal and industrial purposes, but will have no value as illicit drugs. And his work is taking him where few Canadians have gone before: Deep underground into the countrys ultra high-security medicinal marijuana growth facility……..
Original post by Health news from medicineworld.org
No commentsAvastin Improves Ovarian Cancer Treatment
A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovary cancer……..
Original post by Health news from medicineworld.org
No commentsCan your perspective influence your motivation?
Students, athletes and performing artists are often advised to imagine themselves performing successfully. That strategy is believed to motivate them for future exams, games, and shows. But is that motivation influenced by what perspective they take when imagining their performance? Research published by SAGE in the recent issue of Personality and Social Psychology Bulletin explores that question……..
Original post by Health news from medicineworld.org
No commentscomplementary therapies after heart surgery
A new Mayo Clinic study shows that massage treatment decreases pain levels for patients after heart surgery. During a five-month period in 2005, 58 patients undergoing surgery participated in a pilot study to examine the effect of massage on pain after surgery. Of the 30 who received massage, the mean pain scores were less than 1 on a scale of 1 to 10, with 10 as the most painful……..
Original post by Health news from medicineworld.org
No comments